Macquarie Group
SYRE icon

Macquarie Group’s Spyre Therapeutics SYRE Stock Holding History

Macquarie Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,523
Closed -$96 – 2132
2024
Q1 		$96 Buy
+2,523
New +$73.1K ﹤0.01% 1639
2018
Q1 		– Sell
-70
Closed -$9K – 2351
2017
Q4 		$9K Buy
+70
New +$8.56K ﹤0.01% 2281

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Macquarie Group's SYRE Position: Q2 2024 in Review

Macquarie Group sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 2,523 shares — an estimated $96 sold.

Macquarie Group first reported a position in SYRE in Q4 2017 and held it in 2 quarters. The position peaked at $9K in Q4 2017. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Macquarie Group reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 2,523 Spyre Therapeutics shares in Q2 2024, an estimated $96.
  • Macquarie Group first reported a position in Spyre Therapeutics in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Spyre Therapeutics position peaked at $9K in Q4 2017.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.